高压氧或鼓室内类固醇治疗突发性感音神经性聋的辅助疗效
本研究回顾性比较高压氧联合鼓室内类固醇注射与单纯鼓室内类固醇注射治疗突发性感音神经性聋的疗效。结果显示两组在纯音平均听阈、言语识别阈和言语识别率改善上无显著差异;但高压氧可能对类固醇难治患者有价值,超过23次高压氧治疗未观察到额外获益。
要点
- 高压氧联合鼓室内类固醇未显示优于单纯鼓室内类固醇的额外疗效。
- 高压氧可能对类固醇治疗无效的突发性聋患者有益。
- 超过23次高压氧治疗未见额外听力改善。
核心结论
- 辅助同期高压氧治疗未发现额外治疗获益。
- 高压氧可能对类固醇治疗难治的患者有价值。
- 未观察到接受超过23次高压氧治疗的额外获益。
研究设计与样本
- 回顾性研究比较高压氧联合鼓室内类固醇注射与单纯鼓室内类固醇注射的疗效。
- 比较纯音平均听阈、言语识别阈和言语识别率治疗前后改善,并分析应答者与无应答者、治疗延迟及注射/潜水次数。
主要发现
- 两组内治疗前后纯音平均听阈、言语识别阈和言语识别率均显著改善(p < 0.001)。
- 两组间纯音平均听阈、言语识别阈和言语识别率改善无差异(p = 0.49、0.07、0.55)。
- 应答者中4.1%未接受口服类固醇,无应答者中24.4%未接受口服类固醇(p < 0.001)。
- 高压氧应答者听力图改善出现在10.9 ± 6.5次(最多23次)治疗内。
- 25.8%的高压氧应答者在完成鼓室内类固醇注射后无应答,随后在17.5 ± 4.0次高压氧治疗后显示听力图应答。
临床怎么用
- 对于突发性感音神经性聋,高压氧联合鼓室内类固醇不应常规用于所有患者,因未显示额外获益。
- 对类固醇治疗难治的患者,可考虑高压氧治疗,但需注意超过23次治疗无额外获益。
局限性
- 评估突发性感音神经性聋的治疗效果始终受到与该疾病相关的已知混杂因素偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The pathophysiology of sudden sensorineural hearing loss (SSNHL) is still unknown, and therefore treatment strategies are often debated. Traditionally, SSNHL is treated with steroids, either orally (OCS) and/or via intratympanic injection (ITSI). Hyperbaric oxygen treatment (HBOT) has resurged in popularity as an adjunctive therapy. The present study investigated the additive effect of HBOT to traditional steroid treatment for SSNHL. METHODS: Retrospective study comparing treatment effect (pure tone average-PTA; speech recognition threshold-SRT; word recognition score-WRS) between HBOT + ITSI and ITSI treated patients. Sub-analysis of responders and nonresponders, treatment delay, and number of injection/dives. RESULTS: One hundred nineteen patients were divided into ITSI (n = 73) and HBOT + ITSI (n = 46) groups. While there was a significant pre-to-posttreatment improvement in PTA, SRT, and WRS (p < 0.001) within each group, there was no difference between groups in pre-to-postimprovement for PTA, SRT, or WRS (p = 0.49, 0.07, or 0.55, respectively). Of responders to treatment, 4.1% did not receive OCS compared to 24.4% of nonresponders (p < 0.001). In HBOT responders, audiogram improvement was demonstrated within 10.9 ± 6.5 (max 23) sessions. 25.8% of HBOT responders showed no response after completing ITSI and then subsequently demonstrated audiometric response after 17.5 ± 4.0 HBOT dives. CONCLUSION: No additional treatment benefit was found with adjunctive concurrent HBOT. HBOT might be of value to patients refractory to steroid treatment. No beneficial treatment effect in receiving more than 23 HBOT dives was observed. However, evaluating treatment effect in SSNHL loss is always biased by the well-known confounders that are linked to the condition.
引用
- Spiegel JL, De Biasio MJ, Sampieri G, et al. Adjunctive Hyperbaric Oxygen Therapy or Intratympanic Steroids in Sudden Sensorineural Hearing Loss? Laryngoscope. 2025. PMID: 41431852. doi:10.1002/lary.70327
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。